Retinapharma Technologies Inc is categorized under Commercial Biotechnical Research in Tampa, FL and active since 2000.
Retinapharma Technologies Inc was established in 2000, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Carlos Santos at the company’s single location by writing to 324 South Hyde Park Avenue # 350, Tampa, Florida FL 33606 or by phoning (813) 944-3436. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Retinapharma Technologies Inc |
| Contact Person: | Carlos Santos |
| Address: | 324 South Hyde Park Avenue # 350, Tampa, Florida 33606 |
| Phone Number: | (813) 944-3436 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2000 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Retinapharma Technologies Inc was started in 2000 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Carlos Santos for inquiries that concern Retinapharma Technologies Inc by calling the company number (813) 944-3436, as your correspondence is most welcome. Additionally, the physical location of the single location of Retinapharma Technologies Inc can be found at the coordinates 27.940656,-82.463794 as well as the street address 324 South Hyde Park Avenue # 350 in Tampa, Florida 33606.
For its online presence, you may visit Retinapharma Technologies Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.